According to @business, European stocks gained as investors were unmoved by President Donald Trump's threats to impose tariffs on patented drugs, signaling steady risk appetite and a muted sector reaction today; source: Bloomberg, Sep 26, 2025. For traders, the absence of broad de-risking indicates headline risk from potential drug tariffs is not yet repricing European equity exposure, with cross-asset spillovers remaining limited in the session; source: Bloomberg, Sep 26, 2025. The source did not report any direct impact on the crypto market in this update, highlighting no cited linkage to digital asset price action in the report; source: Bloomberg, Sep 26, 2025.